A-317491
A-317491 is a chemical compound that acts as a selective antagonist of the P2X3 receptor, a subtype of the P2X receptor family. These receptors are ligand-gated ion channels that are activated by adenosine triphosphate (ATP) and are involved in various physiological processes, including pain perception and inflammation.
Mechanism of Action[edit | edit source]
A-317491 functions by selectively inhibiting the P2X3 and P2X2/3 receptors, which are predominantly expressed in sensory neurons. These receptors play a crucial role in the transmission of nociceptive signals, which are responsible for the sensation of pain. By blocking these receptors, A-317491 can reduce pain signaling, making it a potential therapeutic agent for the treatment of chronic pain conditions.
Pharmacological Effects[edit | edit source]
Studies have shown that A-317491 effectively reduces pain in various animal models of neuropathic pain, inflammatory pain, and visceral pain. Its ability to selectively target P2X3 receptors without affecting other P2X receptor subtypes makes it a promising candidate for further development as a pain management drug.
Research and Development[edit | edit source]
A-317491 was developed by Abbott Laboratories as part of their research into P2X receptor antagonists. Although it has shown promise in preclinical studies, further research is needed to evaluate its safety and efficacy in humans. The compound's development highlights the potential of targeting purinergic signaling pathways in the treatment of pain and other disorders.
Potential Applications[edit | edit source]
The selective inhibition of P2X3 receptors by A-317491 suggests potential applications in treating conditions such as:
Challenges and Considerations[edit | edit source]
While A-317491 shows potential, challenges remain in translating preclinical findings to clinical success. These include ensuring the compound's safety profile, understanding its pharmacokinetics and pharmacodynamics in humans, and determining the optimal dosing regimen.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
